Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyFidelis Care oncology prior auth policy | OpenPaye…
    Ask Trek AI about this page
    CurrentFidelis CarePolicy N/A

    Oncology medications and supportive agents prior authorization and review

    Customize your policy alerts

    Sign up for all Fidelis Care policy alerts

    Know when Fidelis Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior review/authorization requirements for oncology medications and supportive agents for Medicare - Wellcare by Fidelis Care members, specifying drugs and HCPCS/J-codes that require review by Evolent/New Century Health and which requests are out of scope. It applies to participating providers and describes submission channels.

    Policy Summary
    PayerFidelis Care
    PolicyOncology medications and supportive agents prior authorization and review
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateAug 1, 2024
    Next Review DateN/A
    Key ActionSubmit the entire oncology regimen to Evolent (New Century Health) before dispensing or administration; omissions may result in denial.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    100+listed HCPCS/CPT/J- codes requiring review
    Section I-II-IIIpolicy structure
    Evolentexternal reviewer

    Coverage Criteria and Authorization Preconditions

    Authorization precondition

    Covered when the following administrative conditions are met

    Participating vs non-participating providers: Participating providers must submit requests to Evolent/NCH; non-participating providers must submit requests to the plan via fax at 1-844-235-5090 (effective 10/1/2023).

    Omission of any agent from the submitted oncology regimen to Evolent may result in a denial.

    Out-of-scope services

    Requests that should NOT be submitted to New Century Health (Out of scope)

    Out of scope items: Antibiotics; Bone marrow/stem cell transplants and CAR-T cell therapy; Controlled substances (e.g., morphine); Equipment requests (infusion pumps); Genetic laboratory testing and laboratory services; Hemophilia drugs; Inpatient drug requests; Inpatient radiation and chemotherapy treatments; Iron preparations; Radiopharmaceuticals; Surgeries/surgical procedures; Sickle cell diagnoses and therapies; Immune globulins.

    These items are explicitly listed as out of scope and should NOT be submitted to NCH.

    This policy excludes review by New Century Health (Evolent) for a defined list of out-of-scope services. Do NOT submit requests for the following items to NCH: antibiotics; bone marrow or stem cell transplants and CAR‑T cell therapy; controlled substances (e.g., morphine); equipment requests (for example infusion pumps); genetic laboratory testing and laboratory services; hemophilia drugs; inpatient drug requests; inpatient radiation and chemotherapy; iron preparations; radiopharmaceuticals; surgeries/surgical procedures; sickle cell diagnoses and related therapies; and immune globulins. These exclusions are administrative: they are not routed to NCH for prior review under this policy and should be handled through the appropriate inpatient or plan processes.

    Submission Requirements for Oncology Regimens

    RequirementDetailsCoverage status
    Submit entire oncology regimen to Evolent (formerly New Century Health)
    All oncology regimens (medical and pharmacy benefit agents) must be submitted to Evolent via the NCH web portal (my.newcenturyhealth.com) or by phone (1-888-999-7713, option 1). Non-participating providers must submit requests to the plan via fax (1-844-235-5090).
    Omission of any agent from the submitted oncology regimen may result in a denial.
    Biosimilar class / categoryPreferred biosimilar agents (examples listed in policy)Submission requirement
    Erythropoiesis-stimulating and hematopoietic agents
    Examples include Zarxio (medical & pharmacy benefit) and filgrastim biosimilars (Q5101, Q5110) as listed in the policy.
    Preferred biosimilars still require submission to New Century Health for review prior to dispensing or administration.

    Drug and Code Lists

    Drugs requiring review (mixed list from medical and pharmacy benefit)mixedCovered
    C9142BEVACIZUMAB-MALY.
    J0185APREPITANT INJ.
    J0881DARBEPOETIN ALFA NON-ESRD.
    J1447TBO-FILGRASTIM
    J2506PEGFILGRASTIM (ON-BODY INJECTOR) / PEGFILGRASTIM INJECTION
    J9019ERWINAZE INJ
    J9200FLOXURIDINE INJ
    J9271PEMBROLIZUMAB
    J9317PERTUZUMAB/TRASTUZUMAB/HYAL INJ
    J9355TRASTUZUMAB INJ
    1–10 of 15
    1/2
    Pharmacy benefit only — oral oncology agentsmixedCovered
    J7520SIROLIMUS ORAL
    J8501APREPITANT ORAL
    J8999ABEMACICLIB ORAL
    J8999PALBOCICLIB ORAL

    Provider Submission Instructions and Requirements

    Prior Authorization

    Prior review required by New Century Health

    Oncology medications and supportive agents listed by HCPCS/J-codes must be reviewed by Evolent (formerly New Century Health) before being dispensed at a pharmacy or administered in outpatient/ambulatory settings for participating providers.

    • Includes drugs available via medical or pharmacy benefit and pharmacy-only agents (see HCPCS/J-code lists).
    • Requirement applies to dispensing at a pharmacy or administration in a physician's office, outpatient hospital, or ambulatory setting.
    Step Therapy

    Preferred biosimilars still require submission

    Preferred biosimilar agents remain subject to New Century Health review — preferred status does not remove the requirement to submit the agent to NCH for review.

    • Examples of classes with preferred biosimilars include erythropoiesis-stimulating agents, trastuzumab, bevacizumab, and rituximab.

    Definitions and Out-of-Scope Items

    Out-of-scope — Do not submit to New Century Health
    AntibioticsDo NOT submit requests for antibiotics to New Century Health (out of scope)
    Cellular therapies and transplantsBone marrow/stem cell transplants and CAR‑T cell therapy are out of scope and should not be submitted to NCH
    Inpatient drug and treatment requestsInpatient drug requests and inpatient radiation/chemotherapy treatments are out of scope
    Genetic testing, hemophilia drugs, and immune globulinsGenetic laboratory testing and laboratory services, hemophilia drugs, and immune globulins should NOT be submitted to NCH
    Controlled substances, equipment, and surgeriesControlled substances (e.g., morphine), equipment requests (e.g., infusion pumps), and surgeries/surgical procedures are out of scope
    Radiopharmaceuticals, iron preparations, and sickle cell therapies

    Background

    This administrative policy establishes utilization management for oncology medications and supportive agents by requiring external review by Evolent (formerly New Century Health). Prior review is required for oncology drugs and supportive agents furnished in outpatient/ambulatory settings; participating providers must submit requests to Evolent, and non‑participating providers must submit to the plan via fax as specified. Submit the entire oncology regimen for review—omitting any agent from the submitted regimen may result in a denial. Requests can be submitted via the NCH web portal (my.newcenturyhealth.com) or by phone as provided; non‑participating providers should use the plan fax number.

    Policy Summary
    PayerFidelis Care
    PolicyOncology medications and supportive agents prior authorization and review
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateAug 1, 2024
    Next Review DateN/A
    Key ActionSubmit the entire oncology regimen to Evolent (New Century Health) before dispensing or administration; omissions may result in denial.
    SourceLink
    On This Page
    Coverage Criteria and Authorization PreconditionsSubmission Requirements for Oncology RegimensDrug and Code ListsProvider Submission Instructions and RequirementsDefinitions and Out-of-Scope ItemsBackground
    Documentation Required

    How to submit and what to include

    Submit the entire oncology regimen to Evolent (formerly New Century Health) via the NCH web portal (my.newcenturyhealth.com) or by calling 1-888-999-7713, option 1; non‑participating providers must submit requests to the plan by fax at 1-844-235-5090.

    • Include the full regimen (all medical and pharmacy benefit agents) when submitting.
    • Clinical trials may be sent to Evolent for review.
    Denial Risk

    Denial risk for incomplete regimen submission

    Omission of any agent from the submitted oncology regimen may result in a denial of the request.

    • Ensure every agent in the planned regimen (medical and pharmacy benefit) is listed on the submission.
    • The policy explicitly notes that any omissions may result in denial.
    Radiopharmaceuticals, iron preparations, and sickle cell diagnoses and therapies are excluded from submission to NCH